1. Scrip
  2. >>R&D
  3. >>Clinical Trials

A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

 
• By Jessica Merrill

Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid leukemia patients after a higher rate of deaths was seen.

Leukemia cell (blast cell)

A big setback for Seattle Genetics Inc.'s vadastuximab talirine (SGN-CD33A) in a Phase III acute myeloid leukemia trial will put more pressure on the company's expansion strategy for the currently-marketed lymphoma drug Adcetris (brentuximab vedotin) to drive growth in the near-term.

The Bothell, Washington-based biotech announced June 19 that it is discontinuing all clinical trials studying vadastuximab talirine, including the Phase III CASCADE trial in older AML patients after an imbalance of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.